XAIR - Beyond Air, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.5700
-0.5000 (-12.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.0700
Open3.4900
Bid0.0000 x 2200
Ask0.0000 x 900
Day's Range3.4700 - 3.7400
52 Week Range3.1100 - 6.2490
Volume1079390
Avg. Volume39,387
Market Cap38M
Beta (3Y Monthly)-0.32
PE Ratio (TTM)N/A
EPS (TTM)-1.3750
Earnings DateFeb 11, 2020 - Feb 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.25
  • GlobeNewswire

    Beyond Air Prices $10.5 Million Underwritten Offering of Common Stock and Concurrent Private Placement

    Beyond Air, Inc. (XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the pricing of an underwritten public offering of 2,325,000 shares of its common stock at a price to the public of $3.66 per share. The Company has also granted the underwriters an option for a period of 30 days to purchase up to an additional 348,750 shares of common stock.

  • GlobeNewswire

    Beyond Air Announces Proposed Public Offering and Concurrent Private Placement

    Beyond Air, Inc. (XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares to be issued and sold in the public offering.

  • GlobeNewswire

    Beyond Air Signs Agreement with MESA Specialty Gases & Equipment for Nitric Oxide and Nitrogen Dioxide Calibration Gas Supply

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced an exclusive five-year global supply agreement for NO and NO2 (Nitrogen Dioxide) calibration gas with MESA Specialty Gases & Equipment.

  • GlobeNewswire

    Beyond Air™ Reports Financial Results for Fiscal Second Quarter 2020

    Prioritizing U.S. Investigational Device Exemption (IDE) submission for use of the LungFit™ system in bronchiolitis (BRO) to facilitate completion of the pivotal LungFit™ BRO.

  • GlobeNewswire

    Beyond Air™ to Attend the American Association for Respiratory Care (AARC) 2019 Congress in New Orleans

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced it would be attending the 2019 American Association for Respiratory Care (AARC) being held on November 9-12, 2019 in New Orleans. The company will display and demonstrate LungFit™, its Nitric Oxide (NO) generator and delivery system capable of generating nitric oxide from ambient air, at Booth #1104 on Saturday, November 9 from 10:30 am – 4:00 pm CT; Sunday, November 10 from 9:30 am – 3:00 pm CT; and on Monday, November 11 from 9:30 am to 2:00 pm CT.

  • GlobeNewswire

    Beyond Air™ Schedules Fiscal Second Quarter 2020 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y. and REHOVOT, Israel, Oct. 24, 2019 -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing.

  • GlobeNewswire

    Beyond Air™ to Attend the American Academy of Pediatrics (AAP) National Conference and Exhibition in New Orleans

    GARDEN CITY, N.Y. and REHOVOT, Israel, Oct. 22, 2019 -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing.

  • GlobeNewswire

    Beyond Air™ Provides Update on High Concentration Nitric Oxide (NO) Animal Studies Using LungFit™

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the successful completion of a 30-day rat toxicology study and provided an update on its 12-week toxicology studies in both rats and dogs. All administrations in the studies were done with LungFit™, the company’s proprietary cylinder-free, phasic flow NO generator and delivery system.

  • GlobeNewswire

    Beyond Air™ Presents Data at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced Dr. Abdi Ghaffari, Ph.D., Vice President of Research at Beyond Air presented data at an oral presentation entitled, “High Efficacy of High-dose Nitric Oxide and its Synergistic Effect with Antibiotics against Mycobacterium Abscessus” at the 2019 ERS Congress being held on September 28 - October 2, 2019 in Madrid, Spain.

  • GlobeNewswire

    Beyond Air™ to Present at the Upcoming 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced an oral presentation at the 2019 ERS Congress being held on September 28 - October 2, 2019 in Madrid, Spain. Dr. Abdi Ghaffari, Ph.D., Vice President of Research at Beyond Air Inc., will present the data for the company.

  • GlobeNewswire

    Beyond Air™ to Participate at Two Upcoming Conferences

    GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 12, 2019 -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing.

  • GlobeNewswire

    Beyond Air™ to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate in the 21st Annual H.C. Wainwright Global Investment Conference being held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City. Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.

  • GlobeNewswire

    Beyond Air™ Reports Financial Results for Fiscal First Quarter 2020

    Began trading under new ticker symbol, XAIR, on the NASDAQ stock exchange on July 15, 2019 Anticipate submitting a PMA for LungFit™* for the treatment of persistent pulmonary.

  • GlobeNewswire

    Beyond Air™ Participating at the BTIG Biotechnology Conference on August 12

    Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate in the BTIG Biotechnology Conference being held at the St. Regis Hotel in New York, NY on August 12, 2019. Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.

  • GlobeNewswire

    Beyond Air™ Schedules First Fiscal Quarter 2020 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y. and REHOVOT, Israel, July 30, 2019 -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing.